T E MOON
Overview
Explore the profile of T E MOON including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
113
Citations
1681
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Harris R, Griffith K, MOON T
J Am Acad Dermatol
. 2001 Sep;
45(4):528-36.
PMID: 11568742
This report describes trends in the incidence of various nonmelanoma skin cancers in a region of high ultraviolet exposure. The Southeastern Arizona Skin Cancer Registry routinely identified cases of skin...
2.
Foote J, Harris R, Giuliano A, Roe D, MOON T, Cartmel B, et al.
Int J Cancer
. 2001 Mar;
95(1):7-11.
PMID: 11241303
Risk factors for non-melanoma skin cancer among populations with evidence of precursor damage are not well described. We examined and compared risk factors associated with the development of cutaneous basal-cell...
3.
Cartmel B, MOON T, Levine N, Rodney S, Alberts D
Cancer Epidemiol Biomarkers Prev
. 2000 Sep;
9(9):999-1002.
PMID: 11008922
Maintaining good compliance is a major challenge in long-term cancer chemoprevention trials. Minimizing the number of inactive participants during a trial is an important factor in maximizing compliance. Identifying reasons...
4.
Cartmel B, MOON T, Levine N
Am J Clin Nutr
. 1999 May;
69(5):937-43.
PMID: 10232634
Background: Chemopreventive agents developed to be used in a moderate-risk but otherwise healthy population need to be both efficacious and to have minimal adverse effects. Objective: The objective of this...
5.
Eton O, Legha S, MOON T, Buzaid A, Papadopoulos N, Plager C, et al.
J Clin Oncol
. 1998 Mar;
16(3):1103-11.
PMID: 9508197
Purpose: The current American Joint Commission on Cancer (AJCC) staging system distinguishes between soft tissue and visceral metastases in advanced (stage IV) melanoma. We sought to verify these staging criteria...
6.
Bischoff E, Gottardis M, MOON T, HEYMAN R, Lamph W
Cancer Res
. 1998 Feb;
58(3):479-84.
PMID: 9458093
Recently, we reported that LGD1069, a high-affinity ligand for the retinoid X receptors (RXRs), was shown to have an efficacy equivalent to that of tamoxifen (TAM) as a chemopreventive agent...
7.
Levine N, MOON T, Cartmel B, Bangert J, Rodney S, Dong Q, et al.
Cancer Epidemiol Biomarkers Prev
. 1997 Nov;
6(11):957-61.
PMID: 9367070
The objective of this study was to examine the effect of retinol and isotretinoin on the incidence of nonmelanoma skin cancer in high-risk subjects. A total of 525 participants with...
8.
MOON T, Levine N, Cartmel B, Bangert J, Rodney S, Dong Q, et al.
Cancer Epidemiol Biomarkers Prev
. 1997 Nov;
6(11):949-56.
PMID: 9367069
We conducted a randomized, double-blind, controlled trial to examine the efficacy of retinol supplementation on the incidence of first new nonmelanoma skin cancer in moderate-risk subjects. A total of 2297...
9.
MOON T, Levine N, Cartmel B, Bangert J
Cancer Lett
. 1997 Mar;
114(1-2):203-5.
PMID: 9103292
Two chemoprevention randomized clinical trials were begun in 1984 to evaluate retinoids in the prevention of skin cancers. Moderate risk subjects with a history of at least 10 actinic keratoses...
10.
Hoffman R, Papenfuss M, Buller D, MOON T
Am J Prev Med
. 1996 Jul;
12(4):277-81.
PMID: 8874692
Prostate cancer screening with digital rectal examination (DRE) and prostate-specific antigen (PSA) is recommended by several professional organizations. Our objective was to assess the prostate cancer screening practices and attitudes...